NCT03221179View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

July 5, 2019

Study Completion Date

July 5, 2019

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

RO7049665

A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.

BIOLOGICAL

Placebo

Matching placebo will be administered SC once.

Trial Locations (1)

9471 GP

PRA Health Sciences Early Development Services, Zuidlaren

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03221179 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers | Biotech Hunter | Biotech Hunter